Credit Suisse Ag Altimmune, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Altimmune, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 44,599 shares of ALT stock, worth $387,119. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,599

Holding current value

$387,119

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.22 - $13.81 $366,603 - $615,912	44,599 New	44,599 $454,000
Q1 2023 May 10, 2023	BUY	$4.19 - $16.83 $13,554 - $54,445	3,235 Added 8.48%	41,372 $174,000
Q4 2022 Feb 13, 2023	BUY	$8.74 - $16.45 $333,317 - $627,353	38,137 New	38,137 $627,000
Q2 2022 Aug 12, 2022	BUY	$3.94 - $11.77 $82 - $247	21 New	21 $0
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $12.3 Million - $17.6 Million	-1,410,397 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$8.43 - $16.81 $163,356 - $325,744	-19,378 Reduced 1.36%	1,410,397 $16 Million
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $5.08 Million - $8.48 Million	515,336 Added 56.36%	1,429,775 $14.1 Million
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $3.55 Million - $6.79 Million	-279,280 Reduced 23.4%	914,439 $12.9 Million
Q4 2020 Feb 12, 2021	BUY	$7.84 - $14.22 $9.36 Million - $17 Million	1,193,719 New	1,193,719 $13.5 Million

Others Institutions Holding ALT

# of Institutions

186

Shares Held

39.3M

Call Options Held

913K

Put Options Held

743K

Black Rock Inc. New York, NY

5.32M
Shares

$46.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.98M
Shares

$43.3 Million
0.0% of portfolio
Ameriprise Financial Inc Minneapolis, MN

3.88M
Shares

$33.6 Million
0.01% of portfolio
State Street Corp Boston, MA

3.41M
Shares

$29.6 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

2.75M
Shares

$23.9 Million
1.44% of portfolio

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $426M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account